M&A Consulting for Pharma and Biotech Operators

Pharma operators face recurring decisions about whether to build new capacity internally, acquire existing facilities or platforms, or outsource production to a CDMO. Each path has distinct economics, timelines, regulatory risks, and strategic exposures that vary by modality, scale, and therapy area.

We deliver a structured build, buy, or outsource analysis that compares the three paths across capital intensity, time to operational readiness, regulatory complexity, and long-term strategic fit. The output is a defensible decision framework, supported by transaction comparables and CDMO benchmarks, ready for board and audit committee review.

Strategic decisions in pharma require clear market context: therapy-area economics, competitor positioning, manufacturing supply and demand, and regulatory environment. PharmaBioSource combines public data with proprietary insight from over two decades of pharmaceutical mergers and acquisitions transaction history.

We deliver market opportunity assessments for new product launches, geographic expansion, therapy area entry, and modality migration. Each engagement maps the addressable market, identifies competitive whitespace, profiles the relevant manufacturer and CDMO base, and surfaces the regulatory and reimbursement dynamics that will shape commercial outcomes over the planning horizon.

Pharma manufacturing networks accumulate complexity through acquisitions, modality migration, and shifting demand. PharmaBioSource builds the analytical case for network consolidation: which sites carry strategic value, which are candidates for divestiture, which require capacity expansion, and how the sequence should be executed to protect operational continuity.

The work spans facility-by-facility benchmarking on cost, capacity, regulatory readiness, and strategic fit; modeling of consolidation scenarios against demand projections; and a sequenced execution plan that identifies which sites to divest first and which to consolidate last to maximize realized network value.

Capital decisions in pharma require defensible business cases that survive scrutiny from CFOs, audit committees, and external investors. PharmaBioSource develops investment-ready business cases for facility expansions, acquisitions, divestitures, capacity additions, and therapy-area entry decisions, anchored in operator-level data rather than top-down market sizing.

Each business case includes scenario modeling against market and regulatory variables, clear articulation of strategic rationale, comparable transaction benchmarks, and an executable plan for value capture. Our senior advisors lead the analysis directly, working alongside client finance, strategy, and operating teams through the decision and approval process.

Manufacturing capacity decisions are among the highest-stakes calls in pharma, with multi-year build cycles and capital commitments often exceeding $100M. We provide operator-led capacity evaluation that quantifies effective utilization, identifies bottlenecks, benchmarks productivity against industry standards, and surfaces realistic options for adding, repurposing, or divesting capacity.

The evaluation covers small-molecule, biologic, cell and gene therapy, and sterile injectable modalities. The output — a current-state capacity map, a forward-demand model, and a prioritized set of capacity actions with associated capital requirements, timeline, and risk profile — frequently informs M&A decisions.

PE and VC sponsors investing in pharma manufacturing, CDMOs, life sciences platforms, and therapeutic assets benefit from pharma-specific advisory support from thesis through exit. PharmaBioSource partners with sponsors on thesis development, target screening, commercial and operational diligence, value-creation planning, and exit preparation.

Our advisory work has supported PE and VC firms in CDMO platform investments, biologics manufacturing assets, cell and gene therapy infrastructure, and life sciences real estate.

PharmaBioSource senior advisors have operating experience in the asset classes being underwritten, providing sponsors with operator-level insight into the capital allocation decisions that follow investment.

Pharma deal valuations and operational benchmarks reside in fragmented data sources: SEC filings, regulatory disclosures, deal databases, and proprietary transaction histories. PharmaBioSource aggregates and curates these into actionable pharmaceutical benchmarks for facility valuation, CDMO economics, capacity productivity, and transaction comparables.

The benchmarking work covers facility transaction multiples by modality and region, CDMO contract economics, capital intensity ratios for pharma manufacturing builds, and operational productivity metrics. Engagements range from one-off benchmarks supporting a specific decision to recurring quarterly intelligence subscriptions for in-house corporate development teams.

Pharma supply chain risk has intensified due to pharmaceutical reshoring pressures, geopolitical exposure, single-source vulnerability, and regulatory pressures on supply continuity. We help clients identify alternative suppliers, qualify secondary CDMOs, and restructure supply chains to reduce concentration risk while maintaining cost and quality positions.

The work spans assessment of current supplier dependencies, identification of credible alternates by capability and geography, qualification support, and guidance on contractual negotiation. We are frequently engaged in reshoring initiatives and post-acquisition supply chain integration. Our supplier networks span global CDMOs, raw material producers, and specialized service providers across small-molecule and biologic manufacturing.